Citric Acid for Health & Longevity - Quick Reference Sheet

Citric Acid for Health & Longevity

Created on 08/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Citric acid arrives two ways. As a food additive it slowly and permanently wears away tooth enamel. Taken deliberately as a citrate salt, it counteracts the acid produced by a typical diet: strong human evidence for fewer repeat calcium kidney stones and small gains in bone density in older adults. Costs include stomach upset, potassium load, enamel loss. (Full Review)

Protocol

Standard alkali dose
Potassium citrate 20 milliequivalents twice daily
Or 30–60 milliequivalents daily in divided doses, the range used in the stone and bone trials
Timing and split dosing
Two to three times daily
Plasma half-life is roughly half an hour. An evening dose matters most, since urine is most concentrated and most acidic overnight
Baseline biomarker guidance
Dose set by 24-hour urinary citrate and pH
Not by body weight. Someone already excreting above 800 mg citrate daily has little to gain from dosing at all
Time to effect
Stone-recurrence benefit
1–3 years
Time taken to demonstrate in trials
Bone density gains
12–24 months
Time taken in trials
Urinary citrate and pH
24–48 hours
Shift after the first dose

Benefits

Contraindications
  • Potassium-sparing diuretics
  • Chronic kidney disease stage 4 or worse (filtration below 30 mL/min/1.73 m²)
  • Untreated hyperkalemia (serum potassium above 5.0 mmol/L)
  • Active peptic ulcer disease or delayed gastric emptying (slow-release tablets)
  • Adynamic ileus or any condition delaying gastric passage of solid dosage forms
  • Anticholinergic agents (atropine, benztropine, glycopyrrolate) with slow-release tablets
  • Aluminium-containing antacids with reduced kidney function
  • Severe erosive tooth wear already established
Key Interactions
  • Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (lisinopril, ramipril, losartan, valsartan)
  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac)
  • Aluminium-containing antacids and sucralfate (separate by at least three hours)
  • Iron supplements and iron-fortified foods
  • Potassium supplements and salt substitutes
  • Alkalinising supplements (sodium bicarbonate, potassium bicarbonate, magnesium hydroxide)
  • Renally cleared basic drugs (quinidine, amphetamines, memantine)
  • Protein-restricted and plant-forward diets

Risk & Side Effects

  • High: Gastrointestinal intolerance from citrate salts
  • Medium: Dental erosion; symptomatic hypocalcaemia from intravenous citrate loads
  • Low: Increased absorption of ingested aluminium; hyperkalemia from potassium citrate; promotion of calcium phosphate stones; sodium load from sodium citrate; inflammatory reactions attributed to mould-derived citric acid
  • Speculative: Support of tumour cell fat synthesis by extracellular citrate

Monitoring

Marker Target Why
24-hour urinary citrate > 600 mg/day, ideally > 800 mg/day The direct target of therapy and the predictor of stone risk
24-hour urine pH 6.0–6.5 Confirms alkali delivery without overshoot into calcium phosphate territory
24-hour urinary calcium < 200 mg/day Citrate should lower calcium excretion; failure to do so suggests a separate cause
Serum potassium 4.0–4.5 mmol/L The dose-limiting safety marker for potassium citrate
Serum bicarbonate 24–26 mmol/L Confirms systemic alkali effect and detects low-grade acid retention
Estimated glomerular filtration rate > 90 mL/min/1.73 m², minimum 60 Sets the safe potassium ceiling and tracks the kidney benefit
Serum ferritin and transferrin saturation Ferritin 50–100 ng/mL; saturation 20–40% Citric acid enhances iron absorption, so overload can develop silently
Erosive tooth wear score No established numeric target; change from the individual's own baseline Erosion is the principal irreversible harm and is silent until advanced

Cadence: Serum potassium and bicarbonate at 4 weeks; repeat 24-hour urine at 8–12 weeks; then both every 6–12 months. Bone density at 24 months; dental erosion scoring annually.

Qualitative Assessment

  • Tooth sensitivity to cold, sweet or acidic foods, which often precedes visible erosion
  • Frequency and severity of flank pain or stone-passage episodes
  • Gastrointestinal comfort — bloating, loose stools, reflux — as the main driver of discontinuation
  • Perceived capacity for repeated high-intensity efforts and recovery between them
  • Energy and cognitive clarity, which trial participants did not report changing and which should not be expected to